The development of antimicrobial resistance (AMR) may be inevitable, but this would not be such a problem if there was a supply of new drugs on hand to replace those losing effectiveness. A number of national and international political initiatives have been launched that, alongside promoting stewardship of existing drugs, aim to reinvigorate basic research, foster innovation and remove the roadblocks facing would-be developers of new antibiotics.